SIENNA BIOPHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • July 3rd, 2017 • Sienna Biopharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is effective as of [Date] by and between Sienna Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).
SIENNA BIOPHARMACEUTICALS, INC. (F/K/A SIENNA LABS, INC.)Stock Option Agreement • July 3rd, 2017 • Sienna Biopharmaceuticals, Inc. • Pharmaceutical preparations • California
Unless otherwise defined herein, the terms defined in the 2010 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”).
SIENNA BIOPHARMACEUTICALS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • July 3rd, 2017 • Sienna Biopharmaceuticals, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”), is made by and between Sienna Biopharmaceuticals, Inc., a Delaware corporation (the “Company”) and Paul F. Lizzul (“Executive” and, together with the Company, the “Parties”), effective as of the date the Company’s registration statement relating to the initial public offering of the Company’s common stock becomes effective (the “Effective Date”). This Agreement supersedes in its entirety that certain Employment Agreement by and between Executive and Sienna Labs, Inc. dated as of January 9, 2016 (the “Prior Agreement”).
OFFICE LEASE by and between TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA for the benefit of its Real Estate Account (“Landlord”) and SIENNA BIOPHARMACEUTICALS, INC. a Delaware corporation (“Tenant”) Dated as of May 10, 2016Office Lease • July 3rd, 2017 • Sienna Biopharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS OFFICE LEASE (this “Lease”) is made between TEACHERS INSURANCE AND ANNUITY ASSOCIATION OF AMERICA, for the benefit of its Real Estate Account (“Landlord”), and the Tenant described in Item 1 of the Basic Lease Provisions.
Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. AMENDED AND RESTATED EXCLUSIVE SUPPLY AND LICENSE AGREEMENT by and between NANOCOMPOSIX, INC. a California Corporation and SIENNA BIOPHARMACETICALS, INC. a Delaware corporation...Exclusive Supply and License Agreement • July 3rd, 2017 • Sienna Biopharmaceuticals, Inc. • Pharmaceutical preparations • California
This Amended and Restated Exclusive Supply and License Agreement (“Agreement”) is made as of April 19, 2017 (the “Restatement Date”), by and between Sienna Biopharmceuticals, Inc. (formerly Sienna Labs, Inc.), a Delaware corporation, with its principal place of business at 30699 Russell Ranch Road, Suite 140, Westlake Village, CA 91362 (“SIENNA”), and NANOCOMPOSIX Inc., a California corporation, with its principal place of business at 4878 Ronson Court, Suite K, San Diego, CA 92111 (“NANOCOMPOSIX”). SIENNA and NANOCOMPOSIX may be referred to individually as a “Party” or collectively as the “Parties.”
SIENNA BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT April 12, 2017Investors’ Rights Agreement • July 3rd, 2017 • Sienna Biopharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of April 12, 2017, by and among Sienna Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder.”
FIRST AMENDMENT TO OFFICE LEASEOffice Lease • July 3rd, 2017 • Sienna Biopharmaceuticals, Inc. • Pharmaceutical preparations
Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. THE VENDORS details of whom are set out in Schedule 1 (as Vendors) and SIENNA BIOPHARMACEUTICALS, INC. (as Purchaser) and SHAREHOLDER REPRESENTATIVE SERVICES LLC (as Vendors’...Share Purchase Agreement • July 3rd, 2017 • Sienna Biopharmaceuticals, Inc. • Pharmaceutical preparations • England and Wales
The Vendors wish to sell and the Purchaser wishes to acquire the entire issued share capital of the Company subject to the terms of this Agreement.
Confidential Treatment Requested by Sienna Biopharmaceuticals, Inc. Sienna Labs, Inc. Carlsbad, CA 92011Letter Agreement • July 3rd, 2017 • Sienna Biopharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This letter agreement (the “Agreement”) is to confirm that in connection with the closing of the Series A-3 preferred stock financing of the Company on or about the date hereof and for other good and valuable consideration, the adequacy and sufficiency of which is hereby acknowledged, the Company hereby makes the following covenants to each Stockholder:
